(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 August 2024 (08.08.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/160721 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61P 35/00 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/EP2024/052057

(22) International Filing Date:
29 January 2024 (29.01.2024)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
23154055.0 30 January 2023 (30.01.2023) EP

(71) Applicant: **KYMAB LIMITED** [GB/GB]; The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT (GB).

(72) Inventors: **BILLAUD, Margot**; c/o Kymab Ltd., Patent Department, The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT (GB). **ROWLANDS, Robert**; c/o Kymab Ltd., Patent Department, The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT (GB). **MCCOURT, John Matthew**; c/o Kymab Ltd., Patent Department, The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT (GB). **WAKE, Matthew Stephen**; c/o Kymab Ltd., Patent Department, The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT (GB). **LECOINTRE, Morgane Marie**; c/o Kymab Ltd., Patent Department, The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT (GB). **BARNES, Matthew, Joseph**; c/o Nxera Pharma UK Limited, Granta Park, Great Abington, Cambridge, Cambridgeshire CB21 6DG (GB). **HUTCHINGS, Catherine, Jane**; c/o Nxera Pharma UK Limited, Granta Park, Great Abington, Cambridge, Cambridgeshire CB21 6DG (GB). **BENNETT, Kirstie**; c/o Nxera Pharma UK Limited, Granta Park, Great Abington, Cambridge, Cambridgeshire CB21 6DG (GB). **STOTT, Lisa**; c/o Nxera Pharma UK Limited, Granta Park, Great Abington, Cambridge, Cambridgeshire CB21 6DG (GB).

(54) Title: ANTIBODIES

Figure 11



(57) Abstract: The invention relates to antibodies or antigen-binding fragments thereof which specifically bind to CXCR4. The invention also relates to said antibodies for use in therapy, for use in treating cancer, and for use in treating a solid tumor. The invention also relates to pharmaceutical compositions comprising said antibodies, nucleic acids that encode said antibodies, vectors comprising said nucleic acids, and host cells comprising said nucleic acids or vectors.

WO 2024/160721 A1

[Continued on next page]

(74) **Agent: FORD, Hazel** et al.; Mathys & Squire, The Shard, 32 London Bridge Street, London SE1 9SG (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*